TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Main Feed
Today's Market Intel
Stock Reports
AI Research Reports
Top Stocks
AI-Curated Stock Lists
Commentary
Opinionated Stock Takes
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
IPO Calendar
Upcoming Listings
CommunityDashboard
Log inCreate Account
← Back to TickerSpark
▌Earnings Flash·August 5, 2026

BeOne Medicines AG (ONC) Gains on Earnings Beats

BeOne Medicines AG (ONC) gains 2.6% after reporting earnings beats, lifting shares as investors react to stronger-than-expected results and improved outlook.

Earnings FlashONCHealthcareBiotechnology
By TickerSpark·August 5, 2026·2 min read
BeOne Medicines AG (ONC) Gains on Earnings Beats
▌Key Takeaway
BeOne Medicines AG (ONC) delivered a clean earnings beat, posting $2.05 EPS on $1.71B in revenue versus estimates of $1.66 and $1.62B. Shares rose 2.58% to $331.35, signaling a positive investor response to the stronger-than-expected quarter and reinforcing the company’s growth case.

BeOne Medicines AG (ONC) Earnings Beat, Shares Gain

BeOne Medicines AG (ONC) beat estimates with $2.05 EPS and $1.71B revenue, while shares gained 2.58% to $331.35 in regular-session trading.

Key Numbers

  • EPS: $2.05 actual versus a $1.66 estimate, a beat.

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Revenue: $1.71B actual versus a $1.62B estimate, a beat.
  • Stock reaction: ONC gained 2.58% in regular-session trading, rising from $323.01 to $331.35.
  • Earnings trend: ONC beat EPS estimates in four of the last five listed quarters.
  • Trading activity: Session volume was 171,123.791 versus an average of 317,063.

    • A Double Beat Strengthens ONC’s Growth Case

    This was a broad beat across both major income statement lines. EPS reached $2.05 against a $1.66 estimate, while revenue hit $1.71B against $1.62B. That combination gives BeOne Medicines AG’s growth story fresh support.

    The earnings trend is positive but uneven. ONC beat EPS estimates in four of five listed quarters. The Feb. 26 quarter missed at $0.58 versus a $1.60 estimate, while the latest $2.05 result is the strongest EPS figure in that group. The result also topped the $1.96 EPS reported on May 6.

    The earnings call should put the latest figures in operating context. The useful test is whether the $1.71B revenue and $2.05 EPS result reflects repeatable performance. ONC’s 2.58% gain was constructive, but volume remained below its stated average, pointing to a positive repricing without unusually heavy participation.

    Get AI research on any stock

    Instant reports, daily intelligence, and an AI analyst in your pocket.

    Get Started →

    Bottom Line

    ONC delivered a clean EPS and revenue beat, and the 2.58% regular-session gain confirms a positive initial market response.

    Read the full ONC research report
    ▌Common Questions

    Frequently asked questions

    +Did BeOne Medicines AG (ONC) beat earnings estimates?
    Yes. BeOne Medicines AG reported $2.05 in EPS versus the $1.66 estimate, and revenue came in at $1.71 billion versus the $1.62 billion forecast.
    +How did ONC stock react to the earnings report?
    ONC shares gained 2.58% in regular-session trading, rising from $323.01 to $331.35. The move suggests investors viewed the earnings beat positively.
    +Was BeOne Medicines AG's earnings beat broad-based or just on one metric?
    The beat was broad-based because BeOne Medicines exceeded estimates on both EPS and revenue. That combination is generally stronger than a one-line beat and supports the company’s growth narrative.
    +Has ONC been consistently beating earnings estimates?
    ONC has beaten EPS estimates in four of the last five listed quarters. The latest $2.05 EPS result was also the strongest in that group and above the prior $1.96 EPS reading.
    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌The Full Report

    Want the full picture on ONC?

    The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

    Read the ONC report →Get Full Access →

    Not ready to subscribe? ·

    ▌The Full Report

    Get the full ONC research report

    • Analyst-grade deep dive
    • Charts, valuation, grades
    • Buy/sell price targets
    Read the ONC report →
    ▌For Active Investors

    Smarter research, on every ticker

    • Daily market intelligence
    • On-demand stock analysis
    • AI analyst chat
    Get Full Access →

    Cancel anytime

    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, free in your inbox.

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌More on ONC

    More to read

    All articles
    BeOne Medicines (ONC): BRUKINSA Drives Growth, But Valuation Is Rich
    ONC

    BeOne Medicines (ONC): BRUKINSA Drives Growth, But Valuation Is Rich

    BeOne Medicines is delivering strong oncology growth, led by BRUKINSA and expanding TEVIMBRA sales. The stock earns a Buy, but a premium valuation and product concentration keep the risk profile elevated.

    Aug 6·21 min
    BeOne Medicines AG (ONC) gains on deep earnings beat
    ONC

    BeOne Medicines AG (ONC) gains on deep earnings beat

    BeOne Medicines AG (ONC) gains after a deep earnings analysis of a broad Q2 beat, with EPS and revenue topping estimates, BRUKINSA driving growth, and raised 2026 guidance reinforcing the stock’s measured upside despite an already strong run.

    Aug 5·7 min